# A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

> **NCT06911827** · PHASE1,PHASE2 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 149 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** QLP2117
- **DRUG:** QL2107

## Key facts

- **NCT ID:** NCT06911827
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-09
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 149 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911827, "A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06911827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*